Peddi Prakash, Ajit Nisha Elizabeth, Burton Gary Von, El-Osta Hazem
Louisiana State University Health Sciences Center Shreveport School of Medicine, Shreveport, Louisiana, USA.
Department of Internal Medicine, Louisiana State University Health Sciences Center Shreveport School of Medicine, Shreveport, Louisiana, USA.
BMJ Case Rep. 2016 Dec 23;2016:bcr2016217393. doi: 10.1136/bcr-2016-217393.
Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14.6 months by maximal safe resection with radiation and temozolamide. In the absence of chemotherapy, radiotherapy or chemoradiotherapy, spontaneous regression of GBM or regression while only being on dexamethasone (DEX) and levetiracetam (LEV) have seldom been reported. Here, we present a case of a patient who had significant regression of the GBM with DEX and LEV alone. In this study, we hypothesise a plausible antineoplastic role of DEX and or LEV in GBM and highlight molecular, preclinical and clinical studies supporting this role.
四级星形细胞瘤或多形性胶质母细胞瘤（GBM）患者的中位生存期小于12个月，通过最大限度安全切除并联合放疗和替莫唑胺，生存期可延长至14.6个月。在未进行化疗、放疗或放化疗的情况下，GBM自发消退或仅在使用地塞米松（DEX）和左乙拉西坦（LEV）时消退的情况鲜有报道。在此，我们报告一例仅使用DEX和LEV后GBM显著消退的患者病例。在本研究中，我们推测DEX和/或LEV在GBM中可能具有抗肿瘤作用，并着重介绍支持这一作用的分子、临床前和临床研究。
